The use of the Calvert formula to determine the optimal carboplatin dosage

作者: L. J. C. van Warmerdam , S. Rodenhuis , W. W. ten Bokkel Huinink , R. A. A. Maes , J. H. Beijnen

DOI: 10.1007/BF01218365

关键词:

摘要: Carboplatin is a chemotherapeutic agent frequently used in the treatment of various malignancies. The myelotoxicity and clinical efficacy carboplatin correlate with clearance drug, which correlated to glomerular filtration rate (GFR). Dosing this based solely upon patients body surface area therefore not accurate enough; GFR, thus differ each patient irrespective area. Consequently, some undergo higher systemic exposure, expressed as under plasma concentration/time curve (AUC), than others when dosages are given on basis A high AUC correlates increased toxicity, increasing risks treatment, but case low therapeutical decreases. This indicates that an individual dosing strategy warranted obtain optimal AUC. In article, development application simple equation, known Calvert formula, discussed. formula can be calculate dose accurately order target by using only GFR. is: (mg)=AUC (mg ml−1 min)×[GFR (ml/min)+25 (ml/min)]. has proven be, both retrospective prospective studies, reliable tool carboplatin. Future studies should determine value creatinine measure for

参考文章(35)
Calvert H, Judson I, van der Vijgh Wj, Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. Cancer surveys. ,vol. 17, pp. 189- 217 ,(1993)
V Parsons, E S Garnett, C Chantler, N Veall, Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA. Clinical Science. ,vol. 37, pp. 169- 180 ,(1969)
Donald W. Cockcroft, Henry Gault, Prediction of Creatinine Clearance from Serum Creatinine Nephron. ,vol. 16, pp. 31- 41 ,(1976) , 10.1159/000180580
M. J. Egorin, D. A. Van Echo, J. Aisner, M. Y. Whitacre, S. J. Tipping, E. A. Olman, B. W. Thompson, Pharmacokinetics and Dosage Reduction of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum in Patients with Impaired Renal Function Cancer Research. ,vol. 44, pp. 5432- 5438 ,(1984)
D R Newell, A D Pearson, K Balmanno, L Price, R A Wyllie, M Keir, A H Calvert, I J Lewis, C R Pinkerton, M C Stevens, Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group. Journal of Clinical Oncology. ,vol. 11, pp. 2314- 2323 ,(1993) , 10.1200/JCO.1993.11.12.2314
M E O'Brien, D C Talbot, I E Smith, Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. Journal of Clinical Oncology. ,vol. 11, pp. 2112- 2117 ,(1993) , 10.1200/JCO.1993.11.11.2112
L M Reyno, M J Egorin, R M Canetta, D I Jodrell, K D Swenerton, J L Pater, J N Burroughs, M J Novak, R Sridhara, Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. Journal of Clinical Oncology. ,vol. 11, pp. 1156- 1164 ,(1993) , 10.1200/JCO.1993.11.6.1156
R L Krigel, C S Palackdharry, K Padavic, N Haas, D Kilpatrick, C Langer, R Comis, Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer. Journal of Clinical Oncology. ,vol. 12, pp. 1251- 1258 ,(1994) , 10.1200/JCO.1994.12.6.1251
D S Alberts, S Green, E V Hannigan, R O'Toole, D Stock-Novack, P Anderson, E A Surwit, V K Malvlya, W A Nahhas, C J Jolles, Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. Journal of Clinical Oncology. ,vol. 10, pp. 706- 717 ,(1992) , 10.1200/JCO.1992.10.5.706
Wim J.F. van der Vijgh, Clinical pharmacokinetics of carboplatin. Clinical Pharmacokinectics. ,vol. 21, pp. 242- 261 ,(1991) , 10.2165/00003088-199121040-00002